A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Recruiting · NCT06375733 · Registry updated 2025-08-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-08-12 | NCT06375733 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genfleet Therapeutics (Shanghai) Inc. | 11 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital | Zhengzhou | China | 1 |
| Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute | Nanning | China | 1 |